Meiragtx Holdings Plc (MGTX) Stock Price, Quote & News

Company Profile

MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren's syndrome; AAV-GAD in Phase 2...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 860 7985

Website: meiragtx.com

Address:

450 East 29th Street, 14th Floor, New York, United States

waterlock Aug. 15 at 2:24 AM

$MGTX These are my takes on the report 1. I don't like RIX's primary ept setting (Patient Reported Outcome). It is very subjective. 2. Neuropathic Pain is a very good target. I have seen two other assets targeting this. Massive market. 3. No mention on LCA4 filing, which is not good 4. I like RiboCAR over RiboLeptin. CAR has less preclinical burden and can enter clinical trial quickly and is currently of big pharma interests. 5. 3.4M revenue from JnJ asset agt. This is good. Signals the ongoing of XLRP asset. overall, I don't see much progress, but potentials of the company did not change. I will hold my position.

0 · Reply

MGTX Aug. 15 at 2:22 AM

$MGTX The next catalyst is when j&J’s drug gets final full fda approval. Painful to see such slow progress.

0 · Reply

Helpmrwizard Aug. 15 at 12:57 AM

$MGTX Reviewing the 10Q, the low-key reference to ocular assets (and no mention of accompanying partner interest) speaks louder than words; something could be brewing in my opinion.

1 · Reply

ErnieWorthing84 Aug. 14 at 12:08 PM

$MGTX Damn, xero readout is now late 2026.

1 · Reply

Helpmrwizard Aug. 14 at 2:03 AM

$MGTX short interest musings: June 30th through July 31st stock price increased $1.15 from $6.50 to $7.65, on the back of 435,000 shorted shares being bought back. As of 7/31/2025 the short interest stands at 3,295,000 (nearly "5 days to cover"). Where would the stock price be if the 3,295,000 drops to 1,295,000? Definitely a tail wind no matter how you spin it.

0 · Reply

Bogy99 Aug. 13 at 2:48 PM

$MGTX 8/8/18… 8/7/19….8/6/20….8/11/21….8/11/22….8/10/23….8/12/24…. Earnings have never been reported past the 12th… Bloomberg now has 8/26… but that might be an estimate. What are they waiting for? Hmmmm

1 · Reply

ErnieWorthing84 Aug. 12 at 6:41 PM

$MGTX "I want to see transformative cures reach the American people – including cures for Type 1 diabetes, PEDIATRIC BLINDNESS and PTSD. That’s why we’re working to make the drug development process more user-friendly, while reinforcing its impeccable independence."

3 · Reply

ErnieWorthing84 Aug. 11 at 1:42 PM

$MGTX The good thing about Meira is they don't have to worry about any of the toxicities associated with systemic gtx. All locally targeted.

1 · Reply

broke_millionaire Aug. 10 at 1:32 PM

$SRPT $CAPR $TSHA $MGTX This isnt bearish for sarepts. Vinay prasad is the one who had elevidys reinstated just days before he left the fda

3 · Reply

broke_millionaire Aug. 10 at 1:25 PM

$CAPR $MGTX $SRPT $TSHA

0 · Reply

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results

May 13, 2025, 4:30 PM EDT - 3 months ago

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

May 13, 2025, 8:00 AM EDT - 3 months ago

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

May 9, 2025, 8:00 AM EDT - 3 months ago

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease

Apr 29, 2025, 7:11 AM EDT - 3 months ago

Cone Rod Dystrophy Market Report 2025-2030, with Profiles of SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, MeiraGTx, Ascidian Therapeutics, jCyte, BlueRock Therapeutics and more

Mar 25, 2025, 10:50 AM EDT - 5 months ago

MeiraGTx Holdings: Gaining Regulatory Focus

Mar 13, 2025, 9:51 AM EDT - 5 months ago

MeiraGTx Collaborates With Hologen AI To Expedite Development Of Parkinson's Candidate, Stock Soars

Mar 13, 2025, 8:00 AM EDT - 5 months ago

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

Mar 13, 2025, 7:30 AM EDT - 5 months ago

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process

Feb 21, 2025, 6:30 AM EST - 6 months ago

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

Jan 22, 2025, 4:09 PM EST - 7 months ago

MeiraGTx: 2 Possible Near-Term BLA Filings Could Ignite Shareholder Value

Jan 22, 2025, 8:30 AM EST - 7 months ago

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

Dec 3, 2024, 2:18 PM EST - 9 months ago

MeiraGTx Holdings: Behind The Recent Rally

Oct 15, 2024, 1:32 PM EDT - 10 months ago

MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings

Oct 9, 2024, 4:30 PM EDT - 11 months ago

MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference

Aug 12, 2024, 7:05 AM EDT - 1 year ago

MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results

Aug 12, 2024, 7:03 AM EDT - 1 year ago

MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi

Jul 15, 2024, 11:02 AM EDT - 1 year ago

MeiraGTx: A Very Attractive Longer-Term Play, With Potential Near-Term Catalysts

May 9, 2024, 8:00 AM EDT - 1 year ago

MeiraGTx Reports First Quarter 2024 Financial and Operational Results

Apr 24, 2024, 4:30 PM EDT - 1 year ago

MeiraGTx to Participate in Upcoming Investor Conferences

Apr 18, 2024, 4:30 PM EDT - 1 year ago

MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference

Mar 14, 2024, 8:30 AM EDT - 1 year ago

MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates

Feb 15, 2024, 8:23 AM EST - 1 year ago

MeiraGTx: Bota-Vec Program Advancing With Milestones Being Met

Dec 21, 2023, 7:00 AM EST - 1 year ago

MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million

Nov 14, 2023, 8:00 AM EST - 1 year ago

MeiraGTx Announces Third Quarter 2023 Financial and Operational Results

Oct 30, 2023, 8:28 AM EDT - 1 year ago

MeiraGTx shares jump as Sanofi invests in gene therapy

SNY

Oct 30, 2023, 7:30 AM EDT - 1 year ago

MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities

Oct 24, 2023, 8:30 AM EDT - 1 year ago

MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress

Aug 10, 2023, 8:00 AM EDT - 2 years ago

MeiraGTx Reports Second Quarter 2023 Financial and Operational Results

Aug 1, 2023, 9:10 AM EDT - 2 years ago

MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology

Jul 19, 2023, 8:30 AM EDT - 2 years ago

MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing

Jun 27, 2023, 7:30 AM EDT - 2 years ago

MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Jun 22, 2023, 4:01 PM EDT - 2 years ago

MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company's Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27,

May 11, 2023, 8:00 AM EDT - 2 years ago

MeiraGTx Reports First Quarter 2023 Financial and Operational Results

May 3, 2023, 8:30 AM EDT - 2 years ago

MeiraGTx Announces $60 Million Private Placement of Ordinary Shares

Apr 21, 2023, 8:30 AM EDT - 2 years ago

MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

Mar 14, 2023, 8:00 AM EDT - 2 years ago

MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results

Dec 8, 2022, 4:30 PM EST - 2 years ago

MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022

Oct 4, 2022, 8:00 AM EDT - 3 years ago

MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress

Oct 1, 2022, 10:00 AM EDT - 3 years ago

Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)

Sep 16, 2022, 2:00 AM EDT - 3 years ago

MeiraGTx's Industry-Leading Gene Therapy Manufacturing Facility in Shannon, Ireland Formally Introduced by Head of Irish Government

Aug 11, 2022, 8:30 AM EDT - 3 years ago

MeiraGTx Reports Second Quarter 2022 Financial and Operational Results

Aug 3, 2022, 8:00 AM EDT - 3 years ago

MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing Facilities

Jun 28, 2022, 7:00 AM EDT - 3 years ago

MeiraGTx Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients treated with Botaretigene Sparoparvovec (AAV-RPGR) compared to

May 12, 2022, 8:00 AM EDT - 3 years ago

MeiraGTx Reports First Quarter 2022 Financial and Operational Results

May 4, 2022, 4:01 PM EDT - 3 years ago

MeiraGTx Presents Clinical Data on Botaretigene Sparoparvovec for the Treatment of X-Linked Retinitis Pigmentosa at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting

Apr 19, 2022, 4:30 PM EDT - 3 years ago

MeiraGTx to Participate in Upcoming Investor and Scientific Conferences

Mar 10, 2022, 8:00 AM EST - 3 years ago

MeiraGTx Reports Fourth Quarter and Full Year 2021 Financial and Operational Results

Jan 27, 2022, 8:30 AM EST - 3 years ago

MeiraGTx Receives Clinical Development Milestone Payment from Janssen

Dec 16, 2021, 3:49 PM EST - 3 years ago

A Biotech Unveils Its New Gene Control Technology

waterlock Aug. 15 at 2:24 AM

0 · Reply

MGTX Aug. 15 at 2:22 AM

$MGTX The next catalyst is when j&J’s drug gets final full fda approval. Painful to see such slow progress.

0 · Reply

Helpmrwizard Aug. 15 at 12:57 AM

$MGTX Reviewing the 10Q, the low-key reference to ocular assets (and no mention of accompanying partner interest) speaks louder than words; something could be brewing in my opinion.

1 · Reply

ErnieWorthing84 Aug. 14 at 12:08 PM

$MGTX Damn, xero readout is now late 2026.

1 · Reply

Helpmrwizard Aug. 14 at 2:03 AM

0 · Reply

Bogy99 Aug. 13 at 2:48 PM

1 · Reply

ErnieWorthing84 Aug. 12 at 6:41 PM

3 · Reply

ErnieWorthing84 Aug. 11 at 1:42 PM

$MGTX The good thing about Meira is they don't have to worry about any of the toxicities associated with systemic gtx. All locally targeted.

1 · Reply

broke_millionaire Aug. 10 at 1:32 PM

$SRPT $CAPR $TSHA $MGTX This isnt bearish for sarepts. Vinay prasad is the one who had elevidys reinstated just days before he left the fda

3 · Reply

broke_millionaire Aug. 10 at 1:25 PM

$CAPR $MGTX $SRPT $TSHA

0 · Reply

Universaal Aug. 10 at 12:37 PM

$CAPR $MGTX $SRPT $TSHA it’s a history drugs can’t depend on one person .

1 · Reply

Mamma_m1a Aug. 10 at 10:25 AM

$SRPT Sarepta: Vinay Prasad returns to FDA as head of CBER Vinay Prasad is returning to the Food and Drug Administration to lead the Center for Biologics Evaluation and Research. Prasad left the agency less than two weeks ago amid tensions over Sarepta's (SRPT) Duchenne's muscular dystrophy gene therapy treatment. Health and Human Services spokesperson Andrew Nixon told media outlets Saturday: "At the FDA's request, Dr. Vinay Prasad is resuming leadership of the Center for Biologics Evaluation and Research." Other gene therapy stocks include Capricor Therapeutics ( $CAPR ), Taysha Gene Therapies ( $TSHA ) and MeiraGTx ( $MGTX ). Source: https://thefly.com/landingPageNews.php?id=4180275&headline=SRPT;CAPR;TSHA;MGTX-Vinay-Prasad-returns-to-FDA-as-head-of-CBER

0 · Reply

ErnieWorthing84 Aug. 8 at 10:14 PM

$MGTX https://m.youtube.com/watch?v=gHTcQB_4AFw&pp=0gcJCfwAo7VqN5tD

0 · Reply

BigDaddy_LongTrades Aug. 6 at 11:50 PM

$MGTX one day we are going to wake up and see this at 15.

1 · Reply

ErnieWorthing84 Aug. 5 at 11:29 PM

$MGTX

0 · Reply

ErnieWorthing84 Aug. 5 at 11:17 PM

$MGTX The people at FDA who demanded the maze primary endpoint in XLRP “may not be there anymore” (lul)

1 · Reply

ErnieWorthing84 Aug. 5 at 11:06 PM

$MGTX Minute 29. Head of NIH alluded to MGTX Lc4 in public meeting with FDA and others…

2 · Reply

ErnieWorthing84 Aug. 5 at 10:18 PM

$MGTX https://m.youtube.com/watch?v=RURpD77rc-0

0 · Reply

MGTX Aug. 1 at 11:25 AM

$MGTX Going back down… yet again. Hopefully some good news catalysts come quick.

0 · Reply

ErnieWorthing84 Jul. 31 at 3:56 PM

$MGTX https://www.fiercepharma.com/pharma/prasad-exit-signals-fda-probable-slip-toward-more-permissive-regulation-cell-and-gene?utm_medium=email&utm_source=nl&utm_campaign=LS-NL-FierceBiotech&oly_enc_id=0316A4496778F6E

0 · Reply

waterlock Jul. 31 at 9:58 AM

$MGTX reaching sequential 9 but I suspect that it would end early withassive volume yester day. Get ready! MGTXers

1 · Reply

slinghook67 Jul. 31 at 12:20 AM

$MGTX After Sanofi aquired Blueprint Medicines in June for $9.1B, their CEO Paul Hudson said publicly "Sanofi still retains a sizable capacity for further acquisitions." Just what we want to hear.....

1 · Reply

Market Cap	670.24M
Revenue (ttm)	33.28M
Net Income (ttm)	-147.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-444.08%
Debt to Equity Ratio	2.22

Volume	420,400
Avg Vol	532,718
Day's Range	N/A - N/A
Shares Out	80.37M
Stochastic %K	78%
Beta	1.25
Analysts	Strong Sell
Price Target	$23.00